Characterisation of lung macrophage subpopulations in COPD patients and controls

Jennifer A. Dewhurst1, Simon Lea1, Elizabeth Hardaker2, Josiah V. Dungwa1, Arjun K. Ravi1 & Dave Singh1

Lung macrophage subpopulations have been identified based on size. We investigated characteristics of small and large macrophages in the alveolar spaces and lung interstitium of COPD patients and controls. Alveolar and interstitial cells were isolated from lung resection tissue from 88 patients. Macrophage subpopulation cell-surface expression of immunological markers and phagocytic ability were assessed by flow cytometry. Inflammatory related gene expression was measured. Alveolar and interstitial macrophages had subpopulations of small and large macrophages based on size and granularity. Alveolar macrophages had similar numbers of small and large cells; interstitial macrophages were mainly small. Small macrophages expressed significantly higher cell surface HLA-DR, CD14, CD38 and CD36 and lower CD206 compared to large macrophages. Large alveolar macrophages showed lower marker expression in COPD current compared to ex-smokers. Small interstitial macrophages had the highest pro-inflammatory gene expression levels, while large alveolar macrophages had the lowest. Small alveolar macrophages had the highest phagocytic ability. Small alveolar macrophage CD206 expression was lower in COPD patients compared to smokers. COPD lung macrophages include distinct subpopulations; Small interstitial and small alveolar macrophages with more pro-inflammatory and phagocytic function respectively, and large alveolar macrophages with low pro-inflammatory and phagocytic ability.

Chronic Obstructive Pulmonary Disease (COPD) is characterised by an abnormal inflammatory response to the inhalation of noxious particles such as cigarette smoke1. Macrophage numbers are increased in the small airways of COPD patients2, and there is a correlation between macrophage numbers and COPD severity2–3. Macrophages provide host defence against pathogens, including bacteria, by phagocytosis and activation of both innate and adaptive immune responses through pathogen recognition receptors and antigen presentation respectively4,5.

Macrophages exhibit a degree of plasticity in response to the extracellular environment6, described by the M1/M2 model of macrophage polarisation7. M1 macrophages have pro-inflammatory and cytotoxic properties, and are characterised by Human Leukocyte Antigen (HLA)-DR, Cluster of Differentiation (CD) 14 and CD38 expression. M2 macrophages have anti-inflammatory and tissue repair functions, and are characterised by CD36, CD206, and CD163 expression8–10. This model is simplistic, as macrophages may have both M1 and M2 characteristics11,12. Nevertheless, it is clear that macrophages may form heterogeneous subpopulations with different physiological functions.

It is known that lung macrophages are capable of replication to maintain cell numbers13, and that monocytes can be recruited into the lungs and differentiate into macrophages14,15. Different macrophage subsets have been identified in healthy human lungs, classified as alveolar macrophages, tissue derived monocyte/macrophages and monocyte derived cells16. The movement of monocytes and macrophages within the lungs is not well described, but it is possible that these cells may move between different compartments e.g. from the tissue into the airways.

COPD alveolar macrophages differ from healthy controls, releasing lower levels of pro-inflammatory cytokines in response to Lipopolysaccharide (LPS) stimulation17,18, and showing suppression of M1 related genes19.
COPD alveolar macrophages also have a reduced ability to efferocytose apoptotic epithelial cells and phago-
cytose bacteria. COPD macrophages appear to adopt a unique phenotype in response to local environmen-
tal conditions of oxidative stress and inflammation. “Small” and “large” macrophage subpopulations have been
identified in the sputum of COPD patients, with COPD small macrophages producing increased levels of
pro-inflammatory mediators compared to large macrophages. Small macrophages have also been identified
within the lower airways of patients with cystic fibrosis and interstitial lung disease, while COPD macrophage
subpopulations of different densities have been identified in the lower airways.

We hypothesized that COPD macrophages in the distal lungs comprise distinct subpopulations that can be
defined based on size, and that these subpopulations have different characteristics and functions. This paper
reports an investigation of the characteristics of COPD small and large macrophages in the alveolar spaces and
lung interstitium.

Materials and Methods

Study subjects. 88 patients undergoing surgical resection for suspected lung cancer were recruited and
provided cells that were used for experiments as shown in Fig. 1. The demographics of the entire population
are shown in Table 1, with the characteristics of patients in each experiment shown in the on-line supplement
(Tables S1–S5). COPD was diagnosed based on ≥10 pack years smoking history and GOLD criteria. Controls
were smokers without airflow limitation (smoking controls) or never smokers. Ex-smokers were defined as indi-
viduals who had stopped smoking for ≥1 year. In all the experiments, COPD patients had lower FEV1% predicted
compared to smoking and never smoking controls, and there were no differences in pack year history between COPD patients and smoking controls (Tables S1–S3). COPD current smokers had similar demographic characteristics compared to COPD ex-smokers, with the exception of ex-smokers being older in the flow cytometry experiments. All subjects gave written informed consent. This research was approved by NRES Committee North West- Greater Manchester South (reference 03/SM/396) and all experiments were performed in accordance with relevant guidelines and regulations.

**Macrophage Isolation.** Lung tissue that was far distant and free of tumour was used for experiments, as previously described. Alveolar cells were isolated from resected lung tissue by cannulating the airways and lavaging with 0.1 M NaCl. After lavage the lung tissue was flushed until free of blood before interstitial macrophages were isolated from the lung tissue which was then chopped using a McIlwain™ Tissue Chopper (Campden Instruments, Loughborough, UK) and enzymatically digested. Full methods are described in the online supplement and shown in a flow chart (Fig. S1). Immunohistochemistry of pre- and post-flushed lung tissue for the monocyte/macrophage marker CX3CR1 showed both alveolar macrophages (CX3CR1 positive cells in alveolar space) and blood monocyte (CX3CR1 positive cells in blood vessels) were effectively removed prior to tissue digest for the interstitial population (Fig. S2).

Alveolar and interstitial macrophages were negatively isolated from alveolar and interstitial cells using an EasySep™ human monocyte enrichment kit without CD16 depletion (STEMCELL Technologies, Grenoble, France) according to the manufacturer’s instructions removing cells positive for CD2, CD3, CD19, CD20, CD56, CD66b, CD123 or glycophorin A and red blood cells. Post enrichment granulocyte and lymphocyte content were both <1% in tissue macrophages and <2% and 5% respectively in alveolar macrophages (Fig. S3A and B). Macrophage subpopulations were gated by flow cytometry as shown in Fig. S4. Dendritic cell contamination was ruled out by flow cytometry showing very low levels of cell surface CD123, CD1c or CD1a expression (Fig. S5).

**Measurement of cell- surface markers.** Fluorescently labelled antibodies were validated for their sensitivity using monocyte derived macrophages (explanation in online supplement and shown in Table S6). Antibodies chosen for macrophage subpopulation phenotyping were: CD14 (61D3), CD38 (HIT2), HLA-DR (LN3), CD163 (GH1/61), CD206 (19.2) (all eBioscience, Hatfield, UK), and CD36 (CB38) (BD Biosciences, Oxford, United Kingdom). Flow cytometry method details are in the online supplement. Data are expressed as the percentage of positive cells or median fluorescence intensity (MFI).

**Gene expression.** Alveolar and interstitial macrophages were sorted into subpopulations using a BD Influx cell sorter (BD Biosciences), and RNA was obtained as described in the on-line supplement. Gene expression was analysed using a Custom Made Taqman Assay for gene panels and Taqman gene expression assay for MARCO (Applied Biosystems) as described in the on-line supplement.

**Measurement of alveolar and tissue macrophage diameter in lung resected tissue.** Tissue blocks were obtained from an area of the lung as far distal to the tumour as possible, and processed as described previously. Blocks were dual labelled using anti-human CX3CR1 and CD14 primary antibodies. Further details of methods and antibodies are described in the on-line supplement. The number on macrophages were calculated and the diameter of each measured (see on-line supplement).

**Measurement of CXCL1 and TLR3 by Immunocytochemistry.** Immunocytochemical analysis of CXCL1 and Toll- like receptor (TLR) 3 from cytopsins of alveolar and interstitial macrophages is described in the on-line supplement.

**Measurement of phagocytosis.** Phagocytosis of pHrodo™ green Escherichia coli BioParticles (Life Technologies) by alveolar and interstitial macrophages for 1 hour was quantified by flow cytometry as described in the on-line supplement.

**Statistics.** All statistical analysis was performed using GraphPadInStat (GraphPad Software Inc, La Jolla, California, USA). All data were normally distributed apart from macrophage diameter data. Paired t tests were used to compare flow cytometry cell surface marker expression and gene expression data between small and large macrophages, and between interstitial and alveolar macrophages. Unpaired t tests were used to compare cell surface marker expression, gene expression and phagocytosis data between patient groups. Mann-whitney tests were performed to compare cell diameters between alveolar and interstitial macrophages, while One-way ANOVA followed by Tukey- Kramer Multiple Comparisons Test was used to compare cell diameters between subject groups. One-way ANOVA followed by Tukey- Kramer Multiple Comparisons Test was also used to compare phagocytosis and immunocytochemistry data between small alveolar, large alveolar and small interstitial macrophages. For gene expression analysis, a fold change (FC) >1.5 and p < 0.01 was considered significant; this approach uses a lower p value to account to multiple comparisons, while also a FC threshold for biological relevance. P < 0.05 was considered significant in all other analysis.

**Results**

**Flow Cytometry.** Flow cytometry was performed using cells from 18 COPD patients, of which 13 were used for cell surface marker expression, and 9 smoking controls.

**Identification of small and large macrophages.** Isolated macrophages from 18 COPD patients were used to identify subpopulations of small and large macrophages based on size (FSC) and granularity (SSC) (Fig. 2). These subpopulations were also observed microscopically in both alveolar and interstitial macrophages (Fig. 2C and F respectively).
Alveolar macrophages consisted of similar numbers of small and large cells ($p = 0.11$; Fig. 2G), while interstitial macrophages were mainly small rather than large cells (means 74.5% versus 25.5% respectively, $p < 0.0001$). This pattern was observed in both current and ex-smokers for alveolar macrophages (small 52% versus large 48%; small 54% versus large 46% respectively) and for interstitial macrophages (small 78% versus large 21%; small 70% versus large 29% respectively).

**Cell surface marker expression in COPD macrophages.** Cell surface marker expression on alveolar macrophages was studied in 13 COPD patients, with interstitial macrophages isolated from 11 of these patients using the gating strategy shown in Fig. S4.

Small versus large macrophages: In both alveolar and interstitial cells, small macrophages expressed significantly higher HLA-DR, CD14, CD38 and CD36 and lower CD206 compared to large cells ($p < 0.05$ for each comparison of cell percentages and MFI; Fig. 3). No other cell surface markers showed differences for both cell percentages and MFI on small versus large macrophages.

Alveolar versus interstitial macrophages: CD163 expression (both percentage and MFI) was higher in small alveolar compared to small interstitial macrophages (Fig. 3). No other cell surface markers showed differences for both cell percentages and MFI on small alveolar compared to small interstitial macrophages, or for large alveolar compared to large interstitial macrophages.

Current versus ex-smoking COPD patients: COPD alveolar macrophages were from 7 current and 6 ex-smokers. Large alveolar macrophages showed lower MFI of all markers in current smokers (Fig. 4), with a similar pattern for cell percentages (Table S7). For small alveolar macrophages only HLA-DR showed a decrease in current smokers (Table S7).

Interstitial macrophages were from 6 current smokers and 5 ex-smokers. For large interstitial macrophages, there were significant decreases in CD38 and CD163 MFI caused by current smoking, with numerical trends for a decrease in these markers for cell percentages (Table S7). For small interstitial macrophages, there were few differences between groups with no consistent patterns observed for both MFI and cell percentage results (Table S7).

Sub-analysis of COPD patients using and not using ICS compared (3 versus 10 patients respectively) showed no difference between groups for expression of cell surface markers (Fig. S7).

**Surface markers on COPD patients versus smoking controls.** Cell surface marker expression in COPD alveolar macrophages was compared to smoking controls. The proportions of small and large alveolar macrophages in 18 COPD patients (52% and 48% respectively) and 9 smoking controls (59% and 40% respectively) were similar. CD206 expression on small alveolar macrophages was significantly decreased in COPD patients ($n = 13$) compared to smoking controls ($n = 9$; 11% versus 26% respectively, $p = 0.002$; $p = 0.02$ for MFI analysis) (Table S8). No other differences between subject groups were observed for both MFI and cell percentage results.
Gene expression analysis.  

Alveolar versus interstitial macrophages in COPD patients. Gene expression in alveolar and interstitial macrophages was compared in 8 COPD patients. 67 out of 179 genes measured were significantly changed (Table S9); the majority had increased expression levels in interstitial macrophages, with the most highly regulated shown in Table 2. Alveolar macrophages from 5 COPD current smokers were compared to 3 COPD ex-smokers. There were 6 out of 179 genes with FC > 1.5 (p < 0.01); these are listed in Table S10. No gene expression changes (FC > 1.5; p < 0.01) were observed in interstitial macrophages from COPD current smokers compared to ex-smokers.

Subpopulations of alveolar versus interstitial macrophages in COPD patients. Alveolar and interstitial macrophages were obtained from a different group of 6 COPD patients (demographics in Table S2) and isolated into large and small subpopulations; there were lower numbers of large interstitial cells resulting in insufficient RNA for analysis.

17 genes had significantly higher expression in small interstitial compared to small alveolar macrophages (Table S11). 15 of these genes were also different in whole interstitial compared to whole alveolar macrophages. 42 genes were significantly different in large alveolar compared to small alveolar macrophages (Table S12). The majority of these genes had lower expression in large alveolar macrophages, including IL-10 and vascular endothelial growth factor (VEGF) with fold changes of 0.29 (p = 0.002) and 0.15 (p = 0.0006) respectively.

The 10 most highly up and down regulated genes in whole interstitial, small interstitial and large alveolar macrophages are shown in Table 2. Four genes (interleukin 1 receptor (IL1R) 1, intracellular adhesion molecule 1 (ICAM1), VEGFA and IL1R-like 1 (IL1RL1)) were significantly changed in all 3 analysis; all were increased in

Figure 3. The expression of macrophage markers in small macrophages compared to large macrophages. Flow cytometric analysis of enriched alveolar (A and B) and interstitial (C and D) macrophages for n = 13 and n = 11 COPD patients respectively per marker. Markers analysed were HLA-DR, CD14, CD38, CD36, CD206 and CD163. Data is expressed as the percentage of cells within each subpopulation expressing a specific marker (A and C) and the median fluorescence intensity (MFI) of each marker (B and D) and represents mean (SEM). Paired t test (two tailed) was performed for each marker. * ** *** Significantly increased between size populations within tissue compartment (p < 0.05, 0.01 and 0.001 respectively). #, ##, ### Significantly increased between tissue compartments for each size population (p < 0.05, 0.01 and 0.001 respectively)
interstitial compared to alveolar macrophages (both the whole population and small macrophages only), and were decreased in large compared to small alveolar macrophages.

RNA was isolated from the macrophage subpopulations from a further 8 COPD patients (demographics in Table S2) for the analysis of MARCO expression. MARCO expression was significantly increased in large alveolar macrophages (p < 0.001) compared to both small alveolar and small interstitial macrophages (Fig. S8).

COPD patients versus smoking and never smoker controls. Gene expression changes in the whole alveolar macrophage population were compared using cells from 8 COPD patients, 6 smoking controls and 3 never smokers. There were 5 genes out of 179 significantly changed in COPD patients compared to smoking controls (Table S13). There were 29 genes significantly changed in COPD patients compared to never smokers, with the majority of genes (n = 24) showing up regulation in COPD patients (Table S14). Upregulated genes included those involved in viral recognition or anti-viral response (e.g. toll-like receptor 7 and interferon α receptor) and apoptosis genes, while down-regulated genes included the anti-oxidant superoxide dismutase 1. Only 1 gene was significantly changed in smoking controls compared to never smokers.

Immunocytochemistry. Cell diameter of macrophage subpopulations. Macrophages were identified in peripheral lung tissue from 12 COPD patients, 15 smoking controls and 11 never smokers by expression of CX3CR1 and CD14; all CX3CR1 +ve cells also showed co-expression of CD14. Macrophages located in the alveolar spaces were defined as alveolar macrophages (AM) (white and red arrows Fig. S9) and macrophages located in the alveolar walls or peripheral tissue were defined as interstitial macrophages (IM) (yellow arrows Fig. S9). The median diameter of the alveolar macrophage population was significantly larger than the interstitial macrophage population for never smokers (17.1 µm and 13.2 µm respectively), smoking controls (23.7 µm and 11.3 µm respectively) and COPD patients (23.7 µm and 11.8 µm respectively) (p < 0.001 for all comparisons) Fig. 5A–C. The median diameter of alveolar macrophages was significantly greater in both smoking controls and COPD patients compared to never smokers (p < 0.001 for both comparisons) (Fig. 5E). Interstitial macrophage diameter was significantly greater in never smokers compared to smoking controls (p < 0.01) (Fig. 5D).

Carbon deposits were observed in the cytoplasm of larger cells using light microscopy (Fig. S9D black arrows), although large macrophages were also observed without carbon deposits (Fig. S9D green arrows).

CXCL1 and TLR3 expression in isolated macrophage populations. CXCL1 and TLR3 gene expression levels were higher in small interstitial macrophages compared to small alveolar macrophages (Table 2). We sought to validate these findings by immunohistochemistry. CXCL1 and TLR3 protein expression in samples from 6 COPD patients was investigated in the 3 macrophage subpopulations used for gene expression (small and large alveolar, and small interstitial macrophages). CXCL1 and TLR3 protein expression were numerically highest in small interstitial macrophages and lowest in large alveolar macrophages, thus matching the pattern seen for gene expression (Fig. 6A,B and representative images shown in Fig. S10).
Phagocytosis in COPD alveolar versus interstitial macrophages. Alveolar and interstitial macrophages from 9 COPD patients were used to investigate phagocytosis of E. coli BioParticles. Small alveolar macrophage phagocytosis was significantly higher compared to other macrophage subpopulations, using both the percentage of cells carrying out phagocytosis and MFI (Fig. 6C,D). COPD current (n = 6) and ex-smokers (n = 3) showed no differences for small macrophages, but lower large alveolar phagocytosis in current smokers (Fig. S11). Alveolar macrophages obtained from 6 smoking controls showed greater phagocytosis in small compared to large cells, with similar levels compared to COPD patients (Fig. S11).

Discussion

We identified four macrophage subpopulations in the lower airways and lung tissue of COPD patients using flow cytometry. Based on size and location, we called these small alveolar, large alveolar, small interstitial and large interstitial macrophages, in line with nomenclature previously used to describe lung macrophages. Small macrophages expressed a distinct profile of cell surface markers compared to large macrophages. Furthermore,
small interstitial macrophages had the highest expression of pro-inflammatory genes while large alveolar macrophages had the lowest. Small alveolar macrophages had the greatest phagocytic capacity.

We used immunohistochemistry quantification of cell size to validate our flow cytometry findings showing different macrophage subpopulations. Immunohistochemistry demonstrated a large variation in macrophage cell sizes, confirming the presence of relatively smaller and larger cells. Furthermore, we confirmed our flow cytometry observation that interstitial cells were predominantly smaller cells. Flow cytometry used both size and granularity to distinguish cells, while immunohistochemistry relied on size only. These differences between techniques caution against over-interpretation of the comparison of the proportions of cells categorised as small or large by each method. Nevertheless, both methods showed that larger and smaller cells exist, and that there are proportionally more smaller cells in the interstitium. Additionally, immunohistochemistry provided a comparison against never smokers; smoking controls and COPD patients showed an alveolar macrophage shift towards larger cell size.

Overall, we report a complexity of COPD macrophage phenotypes based on size and location that do not easily fit into the traditional macrophage polarization terminology. It has been accepted for many years that classically activated M1 cells are induced by interferon-γ or LPS and alternatively activated M2 cells are induced by IL-4 or IL-13. More recently, further subtypes of M2 macrophages have been proposed; M2a, M2b and M2c with the idea of macrophage activation existing as a spectrum not a dichotomy. Supporting this concept, Chana et al. reported that COPD macrophages have both M1 and M2b properties. The subpopulations identified here add further to the complexity of macrophage phenotyping, and are now discussed.

**Small Macrophages.** Small macrophages were characterised as HLA-DR\textsuperscript{high}, CD14\textsuperscript{high}, CD38\textsuperscript{high}, CD36\textsuperscript{high} and CD206\textsuperscript{low} relative to large macrophages. HLA-DR and CD14 are centrally involved the innate immune response to pathogens. CD38 controls intracellular calcium levels, thereby enhancing macrophage functions including chemotaxis, cell adhesion, cytokine secretion and phagocytosis. CD36 regulates the effectorcytosis of apoptotic neutrophils. This combination of HLA-DR\textsuperscript{high}, CD14\textsuperscript{high}, CD38\textsuperscript{high} and CD36\textsuperscript{high} therefore seems to identify a pro-inflammatory macrophage subpopulation primed towards enhanced pathogen recognition and phagocytosis. Gene expression analysis supported this concept, as small alveolar macrophages had higher pro-inflammatory gene expression compared to large alveolar macrophages.

Small interstitial macrophages had higher pro-inflammatory gene expression compared to small alveolar macrophages. In contrast, small alveolar macrophages had a greater phagocytic ability compared to small interstitial macrophages. Lung location appears to influence the function of small macrophages.

Different subsets of the mononuclear phagocyte population have been previously categorised in healthy human lungs as alveolar macrophages, tissue derived monocyte/macrophages and monocyte derived cells based on cell surface markers and morphology. These monocyte derived cells are postulated to originate from the blood, and could correspond to our small macrophage populations. This is supported by our finding of low MARCO gene expression in small macrophages; MARCO is expressed at higher levels in embryonic derived
alveolar macrophages compared to recruited myeloid cells/blood monocytes. However, we have recently shown lower blood monocyte recruitment into the lungs of COPD patients compared to controls, suggesting that the increased macrophage numbers in COPD derive from alternative mechanisms such as reduced apoptosis.

CD163 expression was significantly higher in small alveolar compared to small interstitial macrophages. CD163 is a scavenger receptor, and CD163+ macrophages play a role in the resolution of inflammation.

CD163+ alveolar macrophage numbers increase with COPD severity; these CD163+ alveolar macrophages in severe COPD may be predominantly small cells acting to restrict inflammation.

Large Macrophages. Large macrophages were characterised as HLA-DRlow, CD14low, CD38low, CD36low and CD206high relative to small macrophages. CD206 is involved in pathogen recognition. HLA-DR is involved in antigen-presentation to CD4+ T-cells, and our findings suggest reduced antigen-presentation capacity of large alveolar macrophages. HLA-DR expression is also related to the activation state of alveolar macrophages. One could classify these large alveolar macrophages with low functional capacity as M2c macrophages, which are deactivated macrophages. These cells may be involved in immunoregulation, with low functional capacity to prevent further amplification of inflammation in COPD. However, the reduction in IL-10 and VEGF expression does not match with an “M2” classification, although of course this is a simplistic classification.

Acute cigarette smoke exposure in vitro alters macrophage gene expression. Current smoking in COPD patients affected the cell surface marker profile of large macrophages, and not small macrophages; this was most apparent in large alveolar macrophages. The magnitude of changes caused by current smoking were relatively small, and may not be of biological significance. However, the CD206 expression change was relatively large (MFI reduced from 22 to 3) and more likely to be of biological significance. This CD206 down-regulation is compatible with our observation that current smoking decreased COPD large alveolar macrophage phagocytosis capacity.

The higher MARCO gene expression levels in large alveolar macrophages suggest that these cells are derived from embryonic precursors within the lungs rather than recruited from the blood. We observed carbon deposits...
in larger macrophages, but the absence of carbon deposits in many large macrophages indicates that the size of these cells is not simply due to carbon deposition associated with cigarette smoking.

**COPD compared to controls.** Lung cancer surgery is usually performed on patients with a history of smoking. Never smokers are a minority\(^6\), so only a few samples from such patients were available. This limited the scope of the flow cytometry study, with never smokers being included only for gene expression and immunohistochemistry studies where historically collected samples were available. However, smokers without airflow obstruction allowed changes due to COPD rather than chronic smoking to be assessed.

CD206 expression was reduced on COPD compared to smokers small alveolar macrophages. Chana et al. also reported reduced CD206 expression in COPD macrophages compared to controls\(^7\). CD206 plays a role in bacterial recognition\(^8\), and so reduced expression may lead to reduced phagocytosis. Phrdo E. coli BioParticles were used for phagocytosis experiments as a practical and reliable assay. However, E. coli is not commonly isolated in COPD sputum\(^9\). The lack of difference between COPD patients and controls may be due to the type of bacteria used, as impaired COPD macrophage phagocytosis is restricted to certain bacteria including H. influenzae\(^10\).

Immunocytochemistry analysis of cell diameter showed a clear increase in the size of alveolar macrophages in both smokers and COPD patients compared to never smokers. The differences between groups for interstitial macrophages were small and of doubtful relevance. This shift in size caused by long term smoking in alveolar but not interstitial macrophages further underlines that macrophage phenotype changes can be dependent on the specific pulmonary location.

There were significant gene expression differences between COPD and never smoker alveolar macrophages (29 genes), with fewer differences compared to smoking controls. Nevertheless, these findings confirm previous observations that the phenotype of COPD alveolar macrophages is changed compared to controls\(^28, 48–51\). Indeed, the results for COPD patients versus never smoking controls included upregulation of genes involved in apoptosis which has been previously reported in COPD\(^29\).---

**Gene expression.** The gene expression results were filtered to remove false positive results by using a reduced p value (p < 0.01) and a FC threshold of 1.5. The latter allowed removal of genes that are less likely to be biologically relevant due to a smaller magnitude of change. This approach has been used in gene array studies that analyse >40,000 genes\(^30, 53\), which will generate more false positives than our analysis of 179 genes. An alternative statistical method to reduce false positive results in gene array studies is false discovery rate (FDR) analysis\(^34\). Whichever statistical method is used, it is important to further validate the results.

17 genes were significantly changed in small interstitial compared to small alveolar macrophages. In a different group of patients, 15 of these genes were also significantly different in whole interstitial compared to whole alveolar macrophages. These similar results in different patient groups provide a degree of validation. Immunocytochemistry validation was performed for CXCL1 and TLR3 because of the relatively large gene expression differences, and the availability of appropriate immunocytochemistry antibodies. We confirmed that the expression of these proteins was highest in small interstitial macrophages, and lowest in large alveolar macrophages.

The expression of four genes (IL1RL1, ICAM1, VEGFA and IL1R1) was highest in small interstitial macrophages, and lowest in large alveolar macrophages. The function of these genes supports the argument that small interstitial macrophages have the most pro-inflammatory function of the macrophage subsets investigated; IL1R1 is responsible for mediating the pro-inflammatory effects of the IL-1 cytokine family, including IL1RL1\(^35\), VEGFA has a number of functions relevant to angiogenesis as well as being chemotactic for macrophages\(^36\) and granulocytes\(^37\), while ICAM1 is an integrin that can guide chemotaxis in tissues\(^38\).---

The flow cytometry findings combined with the gene expression data indicate that COPD small interstitial macrophages have specialised pro-inflammatory and antigen recognition characteristics, small alveolar macrophages provide phagocytic defence and large alveolar macrophages display a down-regulation of these functions.

**Study limitations.** We used lung samples from patients with a diagnosis of cancer. This is a practical approach used in many previous publications\(^1, 14, 18, 26, 29, 41, 59\). The tissue used was far distant from tumour, reducing any possible influence of the presence of cancer on our results. Furthermore, the similarity of alveolar and interstitial flow cytometry marker expression argues against tumour associated macrophages with unique characteristics being present in our tissue samples, as we would then expect to see a difference in cellular characteristics compared to alveolar cells not in contact with tumour. Overall, it is unlikely that tumour associated macrophages influenced our results. Additionally, corticosteroids can influence the expression of some macrophage markers such as CD16\(^39\). We did not observe any corticosteroid effects in the flow cytometry analysis, and only a minority of the COPD patients were taking these drugs.

**Conclusions** Distinct subpopulations of macrophages exist in the lower airways of COPD patients and controls. We have identified small interstitial macrophages that are pro-inflammatory, small alveolar macrophages that are highly phagocytic and large alveolar macrophages that have low pro-inflammatory and phagocytic ability. The pharmacological targeting of COPD macrophages could be tailored towards the characteristics of specific subpopulations.

**References**

1. Vogelmeier, C. F. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med* 195, 557–582 (2017).
2. Hogg, J. C. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* **350**, 2645–2653 (2004).

3. Di Stefano, A. et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. *Am J Respir Crit Care Med* **158**, 1277–1285 (1998).

4. Fels, A. O. & Cohn, Z. A. The alveolar macrophage. *J Appl Physiol* **60**, 353–369 (1986).

5. Hoppstädter, J. et al. Differential cell reaction upon Toll-like receptor 4 and 9 activation in human alveolar and lung interstitial macrophages. *Respir Res** 11, doi:10.1186/1465-9238-11-124 (2010).

6. Porcheray, E. et al. Macrophage activation switching: an asset for the resolution of inflammation. *Clin Exp Immunol** 142**, 481–489 (2005).

7. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* **41**, 14–20 (2014).

8. Savage, N. D. et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGF-β1. *J Immunol** 181**, 2220–2226 (2008).

9. Cao, H., Wolf, R. G., Meltzer, M. S. & Crawford, R. M. Differential regulation of class II MHC determinants on macrophages by IFN-γ and IL-4. *J Immunol** 143**, 3524–3531 (1989).

10. Muller, U. et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. *J Immunol** 179**, 5367–5377 (2007).

11. Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime reports* 6, doi:10.12703/P-13 (2014).

12. Hume, D. A. The Many Alternative Faces of Macrophage Activation. *Frontiers in immunology* 6, doi:10.3389/fimmu.2015.00370 (2015).

13. Gomez Perdiguero, E. et al. Tissue-resident macrophages originate from yolk-sac-derived erythroid-myeloid progenitors. *Nature* **518**, 547–551 (2015).

14. Ravi, A. K. et al. COPD monocytes demonstrate impaired migratory ability. *Respir Res** 18, doi:10.1186/s12931-017-0569-y (2017).

15. Jansen, W. J. et al. Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury. *Am J Respir Crit Care Med** 184**, 547–560 (2011).

16. Desch, A. N. et al. Flow Cytometric Analysis of Mononuclear Phagocytes in Nondiseased Human Lung and Lung-Draining Lymph Nodes. *Am J Respir Crit Care Med** 193**, 614–626 (2016).

17. Chen, H., Cowan, M. J., Hasday, J. D., Vogel, S. N. & Medvedev, A. E. Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. *J Immunol** 179**, 6097–6106 (2007).

18. Kent, L. M. et al. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-[2-[1-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl]guanidine (SB706504). *J Pharmacol Exp Ther** 328**, 458–468 (2009).

19. Shakhiev, R. et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. *J Immunol** 183**, 2867–2883 (2009).

20. Hodge, S., Hodge, G., Scicchitano, R., Reynolds, P. N. & Holmes, M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. *Immunology and cell biology* **81**, 289–296 (2003).

21. Berenson, C. S., Garlipp, M. A., Grove, L. J., Maloney, J. & Sethi, S. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. *J Infect Dis** 194**, 1375–1384 (2006).

22. Frankenberger, M. et al. Chemokine expression by small sputum macrophages in COPD. *Molecular medicine** 17**, 762–770 (2011).

23. Frankenberger, M. et al. Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers. *Clin Exp Immunol** 138**, 507–516 (2004).

24. Krombach, F. et al. Characterization and quantification of alveolar monocye-like cells in human chronic inflammatory lung disease. *Eur Respir J** 9**, 984–991 (1996).

25. Duan, M. et al. Distinct macrophage subpopulations characterize acute and chronic inflammatory lung disease. *J Immunol** 189**, 946–955 (2012).

26. Wright, A. K. et al. Pivotal Advance: Expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors. *J Leukoc Biol** 86**, 479–489 (2009).

27. Chana, K. K., Fenwick, P. S., Nicholson, A. G., Barnes, P. J. & Donnelly, L. E. Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol** 133**, 207–216, e201-211 (2014).

28. Armstrong, J., Sargent, C. & Singh, D. Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. *Clin Exp Immunol** 158**, 74–83 (2009).

29. Lea, S. et al. The effect of PPAR-gamma ligands on in vitro and in vivo models of COPD. *Eur Respir J** 43**(2), 409–20 (2013).

30. Dalman, M. R., Deeter, A., Nimishakavi, G. & Duan, Z. H. Fold change and p-value cutoffs significantly alter microarray interpretations. *BMC bioinformatics** 13**(Suppl), 2, doi:10.1186/1471-2105-13-S2-S11 (2012).

31. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol** 8**, 958–969 (2008).

32. Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. *Trends in immunology* **25**, 677–686 (2004).

33. Lipscomb, M. E. et al. Human alveolar macrophages: HLA-DR-positive macrophages that are poor stimulators of a primary mixed leucocyte reaction. *J Immunol** 136**, 497–504 (1986).

34. Costabel, U., Bress, K. J., Andreessen, R. & Matthys, H. HLA-DR antigens on human macrophages from bronchoalveolar lavage fluid. *Thorax** 41**, 261–265 (1986).

35. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J. & Mathison, J. C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. *Science** 249**, 1431–1433 (1990).

36. Kang, J. et al. The role of CD38 in Fc gamma receptor (FcgammaR)-mediated phagocytosis in murine macrophages. *J Biol Chem** 287**, 14502–14514 (2012).

37. Savill, J., Hogg, N., Ren, Y. & Haslett, C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. *J Clin Invest** 90**, 1513–1522 (1992).

38. Gibbins, S. L. et al. Transcriptome analysis highlights the conserved difference between embryonic and postnatal-derived alveolar macrophages. *Blood** 126**, 1357–1366 (2015).

39. Kojima, J. et al. Apoptosis inhibitor of macrophage (AIM) expression in alveolar macrophages in COPD. *Respir Res** 14, doi:10.1186/1465-9921-14-30 (2013).

40. Fabriek, B. O., Dijkstra, C. D. & van den Berg, T. K. The macrophage scavenger receptor CD163. *Immunobiology** 210**, 153–160 (2005).

41. Kaku, Y. et al. Overexpression of CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe chronic obstructive pulmonary disease. *PloS One** 9, doi:10.1371/journal.pone.0087400 (2014).
42. Viksman, M. Y., Liu, M. C., Bickel, C. A., Schleimer, R. P. & Bochner, B. S. Phenotypic analysis of alveolar macrophages and monocytes in subjects with allergic rhinitis and asthma. *Am J Respir Crit Care Med* 155, 858–863 (1997).
43. Martinez, F. O., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and polarization. *Front Biosci* 13, 453–461 (2008).
44. Kent, L. et al. Cigarette smoke extract induced cytokine and chemokine gene expression changes in COPD macrophages. *Cytokine* 42, 205–216 (2008).
45. Satnet, I. M. et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. *Clinical cancer research: an official journal of the American Association for Cancer Research* 15, 5626–5645 (2009).
46. Wilson, R. Bacteria, antibiotics and COPD. *Eur Respir J* 17, 995–1007 (2001).
47. Berenson, C. S., Kruzel, R. L., Eberhardt, E. & Sethi, S. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. *J Infect Dis* 208, 2036–2045 (2013).
48. Pons, A. R. et al. Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD. *Eur Respir J* 25, 647–652 (2005).
49. Drommann, D. et al. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. *Respir Res* 6, doi:10.1186/1465-9921-6-68 (2005).
50. Domagala-Kulawik, J., Maskey-Warzchowska, M., Kraszewska, I. & Chazan, R. The cellular composition and macrophage phenotype in induced sputum in smokers and ex-smokers with COPD. *Chest* 123, 1054–1059 (2003).
51. Kunz, L. I. et al. Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. *Respir Res* 12, doi:10.1186/1465-9212-12-34 (2011).
52. Demedts, I. K., Demoor, T., Bracke, K. R., Joos, G. F. & Brusselle, G. G. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. *Respir Res* 7, doi:10.1186/1465-9921-7-53 (2006).
53. Singh, D. et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. *Thorax* 66, 489–495 (2011).
54. Bowler, R. P. et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. *Am J Respir Crit Care Med* 191, 275–284 (2015).
55. Boraschi, D. & Tagliabue, A. The interleukin-1 receptor family. *Seminars in immunology* 25, 394–407 (2013).
56. Riabov, V. et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. *Frontiers in physiology* 5, doi:10.3389/fphys.2014.00075 (2014).
57. Ancelin, M. et al. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. *Laboratory investigation; a journal of technical methods and pathology* 84, 502–512 (2004).
58. Vainer, B. & Nielsen, O. H. Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine. *Aliment Pharmacol Ther* 14, 1023–1031 (2000).
59. Higham, A. et al. The effects of corticosteroids on COPD lung macrophages: a pooled analysis. *Respir Res* 16, doi:10.1186/12931-015-0260-0 (2015).
60. Heasman, S. J. et al. Interferon gamma suppresses glucocorticoid augmentation of macrophage clearance of apoptotic cells. *Eur J Immunol* 34, 1752–1761 (2004).

Acknowledgements

Kathy Banner and Emma Hickman for their intellectual support. This work was partially funded by Novartis Institutes for Biomedical Research and also the North West Lung Centre Charity. This report is independent research supported by National Institute for Health Research South Manchester Respiratory and Allergy Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Author Contributions

Conception and design: J.A.D., S.L., D.S.; Analysis and interpretation: J.A.D., S.L., E.H., J.D., A.R., D.S.; Drafting the manuscript for important intellectual content: J.A.D., S.L., D.S.

Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-07101-2

Competing Interests: D. Singh has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Skypharma, Takeda, Teva, Theraveance and Verona. E. Hardaker was employed by Novartis during the undertaking of this project. S. Lea, J. Dewhurst, J. Dungwa and A. Ravi declare that they have no competing interests

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017